Australian biopharmaceutical company Telix Pharmaceuticals Ltd. (ASX: TLX) has agreed to acquire Swiss/German biotechnology company TheraPharm GmbH from Scintec Diagnostics GmbH to broaden reach to hematologic cancers and transplant medicine, the company said.
Telix will acquire TheraPham for an upfront payment of EUR 10.2m (AUD 16.5m) (USD 12.2m).
The acquisition of TheraPharm provides Telix with access to a portfolio of patents, technologies, production systems, clinical data and know-how in relation to the use of Molecularly Targeted Radiation in hematology and immunology.
Telix Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focussed on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation.
TheraPharm GmbH is a biotechnology company specialised in the research, development and manufacturing of monoclonal antibodies for targeted radiation of hematopoietic malignant and non-malignant diseases, lymphoproliferative diseases, conditioning for allogeneic stem cells as well as in diagnostics of inflammatory diseases and bone marrow metastases.
Fintech Acquires Beverage Industry Data Management and Analytic Provider Aperity
MultiPlan to Acquire Discovery Health Partners for USD 155m
DNA Payments Acquires Active Merchant Services to Expand in UK/EU Core Markets
Pennybacker Capital Partners with M2G to Purchase Tuesday Morning Industrial Space
Dexter Axle Acquires Trailer Axles Supplier Redneck and Redline Products
Rising Phoenix Royalties Acquires 15 PDP Wells in DJ Basin
Falfurrias Capital Acquires Corsis to Boost Data-Enabled Due Diligence Services
Dominion Energy Acquires 150mw Solar Energy Project in Ohio from Invenergy
FleetPride Acquires L and N Truck Service to Expand Services in Southeastern US
CareXM Acquires TouchPointCare to Enhance Care Management Services
Hilb Group Acquires Owen Moore Insurance
Simpli.fi Acquires Advantage Software to Enhance Advertising Services
United Wholesale Mortgage Combines with SPAC Gores Holdings IV